<DOC>
	<DOCNO>NCT01476592</DOCNO>
	<brief_summary>Resveratrol show activate protein call Notch-1 . Signaling Notch-1 show prevent tumor cell growth . Resveratrol also show prevent growth tumor mice . The purpose study examine effect resveratrol Notch-1 neuroendocrine tumor tissue examine people neuroendocrine tumor take resveratrol three month tolerate product .</brief_summary>
	<brief_title>A Biological Study Resveratrol 's Effects Notch-1 Signaling Subjects With Low Grade Gastrointestinal Tumors</brief_title>
	<detailed_description>Patients treat dose 5 gm/day resveratrol orally , two divide dos 2.5 gm without break therapy total three cycle . All patient receive least one dose resveratrol evaluate toxicity tolerability . Toxicities assess every 28 day study drug take patient . Pill bottle review visit well ensure compliance study medication . Toxicities grade accord NCI Common Toxicity Criteria . Blood draw complete blood count comprehensive metabolic panel . In addition , one vial serum store time toxicity assessment later analysis resveratrol level . This level must draw one hour morning dose participant instruct alter time morning dose allow proper timing schedule blood draw . During third cycle treatment , post-treatment biopsy obtain study related purpose process research related purpose .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>1 . ECOG performance status 02 2 . Age &gt; 18 year old 3 . Women postmenopausal must negative enrollment blood test agree use effective mode contraception take study medication 4 . Greater four week must elapse since previous therapy administer neuroendocrine tumor , include surgery , radiation , chemotherapy local liver therapy . 5 . Octreotide use allow must initiate least four week prior enrollment pretreatment biopsy 6 . Able give inform consent willing undergo posttreatment research biopsy 7 . Must able take oral medication without GI tract obstructive symptom 8 . Subjects another malignancy either undergoing treatment chemotherapy radiation , malignancy treatment recommend , would exclude withdrawn study . 9 . Must agree abstain excessive alcohol , define great equivalent three glass wine per day one six pack beer per day 1 . The principal investigator review subject 's current medication prior enrollment study ensure administration Resveratrol affect current medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>gastrointestinal neuroendocrine tumor</keyword>
</DOC>